Author:
Juliusson G, ,Billström R,Gruber A,Hellström-Lindberg E,Höglund M,Karlsson K,Stockelberg D,Wahlin A,Åström M,Arnesson C,Brunell-Abrahamsson U,Carstensen J,Fredriksson E,Holmberg E,Nordenskjöld K,Wiklund F
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference27 articles.
1. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569–3576.
2. Löwenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.
3. Burnett AK, Wheatley K, Goldstone AH, Gibson B, Webb D, Prentice AG et al. MRC AML12: a comparison of ADE vs MAE and S-DAT vs H-DAT±retinoic acid for induction and four vs five total courses using chemotherapy or stem cell transplantation in consolidation, in 3459 patients under 60 years with AML. Blood 2002; 100 (11(suppl)): 155a.
4. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997; 89: 2311–2318.
5. Hiddemann W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A et al. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk Lymphoma 1993; 10 (Suppl): 133–137.